---
input_text: Hematopoietic Cell Transplantation Outcomes among Medicaid and Privately
  Insured Patients with Sickle Cell Disease.Compared with privately insured patients,
  recipients of Medicaid have been reported to have worse outcomes in several clinical
  conditions and following various surgical and medical procedures. However, the relationship
  between health insurance status and allogeneic hematopoietic cell transplantation
  (alloHCT) outcomes among patients with sickle cell disease (SCD) is not well described.
  We sought to compare alloHCT outcomes between patients with SCD who underwent alloHCT
  while enrolled on Medicaid versus those who underwent alloHCT while covered by private
  health insurance. We conducted a retrospective multicenter study using data reported
  to the Center for International Blood and Marrow Transplant Research. US patients
  enrolled on Medicaid or private insurance who underwent a first alloHCT for SCD
  between 2008 and 2018 were eligible for this study. The primary outcome was event-free
  survival (EFS), defined as time to death or graft failure. Secondary outcomes included
  overall survival (OS), graft failure, acute graft-versus-host disease (GVHD), and
  chronic GVHD. Univariate analysis was performed using the Kaplan-Meier method for
  EFS and OS. The proportion of patients with graft failure, acute GVHD, and/or chronic
  GVHD was calculated using the cumulative incidence estimator to accommodate competing
  risks (ie, death). Cox regression was used to identify factors associated with EFS,
  OS, graft failure, and acute and chronic GVHD. A total of 399 patients (Medicaid,
  n = 225; private insurance, n = 174) were included in this study. The median duration
  of follow-up was 34 months (range, 1.0 to 134.7 months) for the Medicaid group and
  38.7 months (range, 0.3 to 139.3 months) for the private insurance group. Compared
  with the patients with private insurance, those on Medicaid had a significantly
  lower 3-year EFS (75.4% [95% confidence interval (CI), 69.4% to 81%] versus 82.2%
  [95% CI, 76.9% to 87.8%]; P = .0279) and a significantly higher 3-year cumulative
  incidence of graft failure (17.2% [95% CI, 12.5% to 22.5%] versus 10.5% [95% CI,
  6.4% to 15.4%]; P = .0372). There were no significant between-group differences
  in 3-year OS (P = .6337) or in the cumulative incidence of acute GVHD (P = .4556)
  or chronic GVHD (P = .6878). Cox regression analysis after adjusting for other significant
  variables showed that the patients enrolled on Medicaid had a lower EFS (hazard
  ratio [HR], 2.36; 95% CI, 1.44 to 3.85; P = .0006) and a higher cumulative incidence
  of graft failure (HR, 2.57; 95% CI, 1.43 to 4.60; P = .0015), with no significant
  between-group differences in OS (HR, 0.99; 95% CI, 0.47 to 2.07; P = .9765), acute
  GVHD (HR, 0.94; 95% CI, 0.59 to 1.49; P = .7905), or cGVHD (HR, 0.98; 95% CI, 0.65
  to 1.48; P = .9331). That EFS is worse in patients on Medicaid compared with privately
  insured individuals following alloHCT for SCD provides the rationale for research
  to better understand the mechanisms by which insurance status impacts alloHCT outcomes
  among patients with SCD.
raw_completion_output: |-
  primary_disease: Sickle Cell Disease (SCD)
  medical_actions: allogeneic hematopoietic cell transplantation (alloHCT); retrospective multicenter study; Kaplan-Meier method; cumulative incidence estimator; Cox regression
  symptoms: death; graft failure; acute graft-versus-host disease (GVHD); chronic GVHD
  chemicals: 
  action_annotation_relationships: allogeneic hematopoietic cell transplantation (alloHCT) TREATS death IN Sickle Cell Disease (SCD); allogeneic hematopoietic cell transplantation (alloHCT) TREATS graft failure IN Sickle Cell Disease (SCD); retrospective multicenter study ASSESSES allogeneic hematopoietic cell transplantation (alloHCT) OUTCOMES IN Sickle Cell Disease (SCD); Kaplan-Meier method USED FOR analyzing event-free survival (EFS) IN Sickle Cell Disease (SCD); cumulative incidence estimator USED FOR calculating graft failure; acute GVHD; chronic GVHD IN Sickle Cell Disease (SCD); Cox regression USED FOR identifying factors associated with EFS; OS; graft failure; acute and chronic GVHD IN Sickle Cell Disease (SCD)
prompt: |+
  Split the following piece of text into fields in the following format:

  subject_extension: <A chemical or drug mentioned in the relationship between the medical action and the symptom, for example, "analgesic agent therapy" has the aspect "analgesic">
  object_extension: <An optional term describing some specific aspect of the object, e.g. "analgesic agent therapy" has the aspect "analgesic">
  subject: <The medical action. For example: blood transfusion, radiation therapy, cardiac catheterization, pulse oximetry, otoscopy>
  predicate: <The relationship type between the medical action and the symptom, usually TREATS or PREVENTS.>
  object: <A sign or symptom associated with the disease and targeted by the medical action. For example, Low serum calcitriol, hypoplasia of the thymus, chronic cough, aortic stiffness, low pulse pressure>
  qualifier: <The primary disease the relationship is about, or specifically the disease the symptom is related to. For example, Beck-Fahrner syndrome, hereditary retinoblastoma, progeria, diabetes mellitus, infectious otitis media>
  subject_qualifier: <An optional qualifier or modifier for the subject of the statement, e.g. "high dose" or "intravenously administered">
  object_qualifier: <An optional qualifier or modifier for the object of the statement, e.g. "severe" or "with additional complications">


  Text:
  acute and chronic GVHD IN Sickle Cell Disease (SCD)

  ===

extracted_object:
  primary_disease: MONDO:0007374
  medical_actions:
    - allogeneic hematopoietic cell transplantation (alloHCT)
    - retrospective multicenter study
    - Kaplan-Meier method
    - cumulative incidence estimator
    - Cox regression
  symptoms:
    - death
    - graft failure
    - acute graft-versus-host disease (GVHD)
    - chronic GVHD
  action_annotation_relationships:
    - subject: allogeneic hematopoietic cell transplantation
      predicate: TREATS
      object: death
      qualifier: MONDO:0007374
    - subject: allogeneic hematopoietic cell transplantation (alloHCT)
      predicate: TREATS
      object: graft failure
      qualifier: MONDO:0007374
    - subject: ASSESSES allogeneic hematopoietic cell transplantation OUTCOMES
      predicate: ASSESSES
      object: OUTCOMES
      qualifier: MONDO:0011382
      subject_qualifier: retrospective multicenter study
      subject_extension: allogeneic hematopoietic cell transplantation
    - subject: Kaplan-Meier method
      predicate: USED FOR
      object: HP:0045029
      qualifier: MONDO:0007374
    - subject: <cumulative incidence estimator>
      predicate: <USED FOR>
      object: <calculating graft failure>
      subject_extension: <cumulative incidence estimator>
    - subject: chronic GVHD
      predicate: IN
      qualifier: MONDO:0007374
    - subject: <Cox regression>
      predicate: <USED FOR>
      object: <identifying factors associated with EFS>
      qualifier: <Not specified>
      subject_qualifier: <Not specified>
      object_qualifier: <Not specified>
      subject_extension: <Not applicable>
      object_extension: <Not applicable>
    - predicate: IN
      object: acute and chronic GVHD
      qualifier: MONDO:0007374
named_entities:
  - id: MONDO:0007374
    label: Sickle Cell Disease (SCD)
  - id: CHEBI:44423
    label: Hydroxyurea
  - id: CHEBI:18050
    label: L-glutamine
  - id: MAXO:0001298
    label: therapy
  - id: MONDO:0011382
    label: Sickle Cell Disease
  - id: MONDO:0005290
    label: Rhabdomyolysis
  - id: MAXO:0001121
    label: kidney biopsy
  - id: MAXO:0000387
    label: muscle biopsy
  - id: HP:0001919
    label: acute kidney injury (AKI)
  - id: CHEBI:7044
    label: Myoglobin
  - id: MAXO:0000950
    label: supportive care
  - id: CHEBI:4027
    label: cyclophosphamide
  - id: MAXO:0000747
    label: hematopoietic stem cell transplantation (HSCT)
  - id: MAXO:0009101
    label: early intervention
  - id: MONDO:0100096
    label: COVID-19
  - id: MAXO:0000756
    label: blood transfusion
  - id: MAXO:0001001
    label: gene therapy
  - id: HP:0004936
    label: venous thrombosis
  - id: MONDO:0005266
    label: diabetic retinopathy
  - id: MONDO:0002303
    label: central retinal vein occlusion
  - id: HP:0100543
    label: Cognitive dysfunction
  - id: MONDO:0013517
    label: beta-thalassemia
  - id: HP:0012531
    label: Pain
  - id: MAXO:0000457
    label: Pain management
  - id: HP:0000739
    label: anxiety
  - id: HP:0000716
    label: depression
  - id: CHEBI:6716
    label: depot medroxyprogesterone (DMPA)
  - id: CHEBI:59826
    label: progestin
  - id: MONDO:0002049
    label: Thrombocytopenia
  - id: MAXO:0001017
    label: Vaccination
  - id: MONDO:0005632
    label: Acute chest syndrome
  - id: CHEBI:41879
    label: dexamethasone
  - id: CHEBI:17303
    label: morphine
  - id: CHEBI:16480
    label: nitric oxide
  - id: CHEBI:28304
    label: heparin
  - id: MONDO:0013730
    label: graft versus host disease (GvHD)
  - id: MAXO:0010030
    label: Bone marrow transplantation
  - id: MAXO:0000004
    label: Surgical intervention
  - id: HP:0200023
    label: Priapism
  - id: HP:0001945
    label: pyrexia
  - id: HP:0002019
    label: constipation
  - id: HP:0001903
    label: decreased haemoglobin
  - id: CHEBI:26710
    label: NaCl
  - id: MAXO:0000530
    label: Carrier screening
  - id: HP:0002615
    label: Hypotension
  - id: HP:0001662
    label: Bradycardia
  - id: HP:0002098
    label: Respiratory distress
  - id: CHEBI:119915
    label: Fentanyl
  - id: HP:0000407
    label: Sensorineural hearing loss (SNHL)
  - id: HP:0001249
    label: Poor school performance
  - id: HP:0030645
    label: Risk of (central) auditory processing disorder
  - id: CHEBI:28901
    label: Busulfan
  - id: MAXO:0000750
    label: conditioning regimen
  - id: MONDO:0002280
    label: Anemia
  - id: MONDO:0005003
    label: Chronic Pancreatitis
  - id: MAXO:0000088
    label: Dietary interventions
  - id: MAXO:0035049
    label: Endoscopic retrograde cholangiopancreatography
  - id: CHEBI:35480
    label: Analgesic
  - id: CHEBI:22586
    label: Antioxidants
  - id: CHEBI:17334
    label: Penicillin
  - id: HP:0001297
    label: stroke
  - id: HP:0003826
    label: Stillbirths
  - id: HP:0100806
    label: Sepsis
  - id: HP:0011891
    label: Postpartum hemorrhage
  - id: MONDO:0002050
    label: Depression
  - id: HP:0012418
    label: Hypoxia
  - id: CHEBI:17230
    label: Homocysteine
  - id: CHEBI:16811
    label: Methionine
  - id: MONDO:0005136
    label: Malaria
  - id: HP:0001518
    label: Low birth weight
  - id: CHEBI:38068
    label: Antimalarial
  - id: MONDO:0001754
    label: Eclampsia
  - id: HP:0011902
    label: Abnormal hemoglobin
  - id: CHEBI:223316
    label: Artemisinin
  - id: CHEBI:195280
    label: Artemether
  - id: CHEBI:156095
    label: Lumefantrine
  - id: CHEBI:63918
    label: Artesunate
  - id: CHEBI:2674
    label: Amodiaquine
  - id: MAXO:0009065
    label: Intravenous push (IVP) analgesia
  - id: MONDO:0010088
    label: Musculoskeletal diseases (MSD)
  - id: MONDO:0002081
    label: Musculoskeletal diseases
  - id: MONDO:0002146
    label: Hypogonadism
  - id: MONDO:0009061
    label: cystic fibrosis
  - id: MAXO:0000079
    label: genetic counseling
  - id: MONDO:0020380
    label: Sickle Cell Anaemia (SCA)
  - id: HP:0001511
    label: intrauterine growth restriction
  - id: HP:0100602
    label: pre-eclampsia
  - id: HP:0005268
    label: miscarriage
  - id: HP:0001622
    label: preterm delivery
  - id: HP:0011419
    label: placental abruption
  - id: CHEBI:15365
    label: aspirin
  - id: CHEBI:15552
    label: prostacyclin
  - id: CHEBI:26995
    label: thromboxane
  - id: MAXO:0001077
    label: Splenectomy
  - id: HP:0010972
    label: Ineffective erythropoiesis
  - id: HP:0004387
    label: enterocolitis
  - id: MONDO:0007100
    label: transthyretin amyloidosis
  - id: HP:0001139
    label: conditional transcranial Doppler (TCD) flow velocities
  - id: MAXO:0010203
    label: Echocardiography
  - id: HP:0001712
    label: Left Ventricular Hypertrophy
  - id: HP:0001699
    label: Sudden death
  - id: CHEBI:15956
    label: Biotin
  - id: HP:0000689
    label: malocclusion
  - id: HP:0009102
    label: anterior open bite
  - id: HP:0000347
    label: mandibular retrusion
  - id: MAXO:0035088
    label: Brain magnetic resonance imaging (MRI)/magnetic resonance angiography (MRA)
  - id: HP:0002090
    label: Pneumonia
  - id: HP:0012330
    label: Pyelonephritis
  - id: HP:0003811
    label: Neonatal death
  - id: MAXO:0000127
    label: Genetic testing
  - id: HP:0001394
    label: Cirrhosis
  - id: CHEBI:68554
    label: Deferiprone
  - id: CHEBI:4356
    label: Deferoxamine
  - id: CHEBI:49005
    label: Deferasirox
  - id: HP:0012378
    label: Fatigue
  - id: MONDO:0024533
    label: Pulmonary hypertension (PHT)
  - id: HP:0002875
    label: Exertional dyspnea
  - id: HP:0001962
    label: Palpitation
  - id: HP:0100749
    label: Chest pain
  - id: CHEBI:80234
    label: BNP
  - id: MONDO:0005149
    label: Pulmonary hypertension
  - id: MONDO:0044348
    label: Hemoglobinopathies
  - id: HP:0000026
    label: Testicular failure
  - id: HP:0000789
    label: Infertility
  - id: CHEBI:31709
    label: Iohexol
  - id: CHEBI:16737
    label: creatinine
  - id: HP:0007760
    label: Sickle cell disease (SCD)
  - id: MAXO:0000600
    label: Renal replacement therapy
  - id: MAXO:0000515
    label: Extracorporeal membrane oxygenation
  - id: MAXO:0000900
    label: Electrocardiography
  - id: HP:0005184
    label: Prolonged QTc interval
  - id: HP:0002653
    label: Bone pain
  - id: CHEBI:5790
    label: Hydromorphone
  - id: HP:0002140
    label: ischemic strokes
  - id: CHEBI:143719
    label: Hib
  - id: CHEBI:143712
    label: menC
  - id: MONDO:0010434
    label: homozygous sickle cell (SS) disease
  - id: CHEBI:8455
    label: Proguanil
  - id: CHEBI:8673
    label: Pyrimethamine
  - id: HP:0001263
    label: Developmental delay
  - id: MONDO:0010094
    label: Sickle cell trait (SCT)
  - id: MAXO:0000139
    label: Autopsy
  - id: HP:0004870
    label: Chronic hemolytic anemia
  - id: MAXO:0000882
    label: behavioral modification
  - id: HP:0012532
    label: chronic pain
  - id: HP:0003256
    label: coagulopathy
  - id: HP:0001873
    label: Thrombocytopenia
  - id: HP:0001974
    label: Leukocytosis
  - id: MONDO:0005399
    label: venous thromboembolism (VTE)
  - id: HP:0002625
    label: deep vein thrombosis (DVT)
  - id: HP:0002204
    label: pulmonary embolism (PE)
  - id: MAXO:0001479
    label: Allogeneic hematopoietic stem cell transplantation (allo-HSCT)
  - id: CHEBI:80240
    label: Endothelin-1
  - id: HP:0000083
    label: Kidney failure
  - id: HP:0001399
    label: Liver failure
  - id: HP:0030718
    label: right atrial enlargement
  - id: HP:0001667
    label: right ventricular hypertrophy
  - id: HP:0200128
    label: biventricular hypertrophy
  - id: HP:0012250
    label: ST depression
  - id: CHEBI:22315
    label: Alkaloids
  - id: CHEBI:26848
    label: Tannins
  - id: CHEBI:22580
    label: Anthraquinones
  - id: CHEBI:15889
    label: Sterols
  - id: CHEBI:26605
    label: Saponins
  - id: CHEBI:26195
    label: Polyphenols
  - id: CHEBI:26873
    label: Terpenoids
  - id: CHEBI:15882
    label: Phenols
  - id: CHEBI:83970
    label: Cardiac glycosides
  - id: HP:0000819
    label: diabetes
  - id: HP:0000822
    label: hypertension
  - id: HP:0002664
    label: cancer
  - id: CHEBI:82557
    label: treosulfan
  - id: HP:0030157
    label: flank pain
  - id: HP:0030830
    label: Crackles
  - id: HP:0002637
    label: Cerebral ischemia
  - id: HP:0002617
    label: Vasculopathy
  - id: HP:0001788
    label: Premature rupture of membranes
  - id: HP:0001510
    label: Growth failure
  - id: HP:0004322
    label: Short stature
  - id: MONDO:0003664
    label: Haemolytic anaemia
  - id: HP:0001923
    label: reticulocytosis
  - id: HP:0025435
    label: increased lactate dehydrogenase levels
  - id: HP:0011981
    label: pigment gallstones
  - id: HP:0001907
    label: thromboembolism
  - id: HP:0001878
    label: Haemolytic anaemia
  - id: MAXO:0000021
    label: Palliative care (PC)
  - id: HP:0010885
    label: bone infarctions
  - id: CHEBI:50858
    label: corticosteroids
  - id: MAXO:0000617
    label: Pulse oximetry
  - id: CHEBI:74213
    label: ribonucleotide reductase (rnr) inhibitors
  - id: HP:0002315
    label: Headache
  - id: HP:0003281
    label: High ferritin levels
  - id: HP:0004325
    label: Low weight
  - id: HP:0001635
    label: heart failure
  - id: HP:0002099
    label: asthma
  - id: HP:0003040
    label: joint disorders
  - id: MAXO:0000149
    label: Healthcare transition (HCT) intervention
  - id: HP:0001894
    label: High platelet count
  - id: MAXO:0000757
    label: infusion
  - id: MONDO:0005096
    label: Sickle cell crisis (SCC)
  - id: MAXO:0000087
    label: Massage
  - id: MAXO:0000969
    label: optical coherence tomography
  - id: MONDO:0005775
    label: Glucose-6-phosphate dehydrogenase deficiency
  - id: MAXO:0000058
    label: Pharmacological treatment
  - id: CHEBI:125354
    label: Plerixafor
  - id: HP:0045029
    label: analyzing event-free survival (EFS)
